# Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

> **NCT06311214** · PHASE2 · RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 500 (estimated)

## Conditions studied

- Advanced Malignant Solid Neoplasm
- Metastatic Malignant Solid Neoplasm

## Interventions

- **PROCEDURE:** Biopsy Procedure
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Echocardiography Test
- **OTHER:** Electronic Health Record Review
- **DRUG:** Enfortumab Vedotin
- **OTHER:** Immunohistochemistry Staining Method
- **PROCEDURE:** Magnetic Resonance Imaging
- **PROCEDURE:** Multigated Acquisition Scan
- **BIOLOGICAL:** Sacituzumab Govitecan
- **BIOLOGICAL:** Trastuzumab Deruxtecan

## Key facts

- **NCT ID:** NCT06311214
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-18
- **Primary completion:** 2028-03-31
- **Final completion:** 2028-03-31
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2026-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06311214

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06311214, "Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)". Retrieved via MORVS 2026-10-14 from https://api.morvs.ai/clinical/NCT06311214. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*